Egbers Lieke, Grotenhuis Anne J, Aben Katja K, Alfred Witjes J, Kiemeney Lambertus A, Vermeulen Sita H
Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands.
Int J Cancer. 2015 Mar 1;136(5):1117-24. doi: 10.1002/ijc.29062. Epub 2014 Jul 9.
A history of urinary bladder cancer (UBC) in first-degree relatives increases UBC risk by twofold. The influence of positive family history on UBC prognosis is unknown. Here, we investigated association of first-degree UBC family history with clinicopathological characteristics and prognosis of UBC patients. Detailed clinical data of 1,465 non-muscle-invasive bladder cancer (NMIBC) and 250 muscle-invasive or metastatic bladder cancer (MIBC) patients, diagnosed from 1995 to 2010, were collected through medical file review. Competing risk analyses were used to compare recurrence-free survival (RFS) and progression-free survival (PFS) of NMIBC patients according to self-reported UBC family history. Overall survival in MIBC patients was estimated using Kaplan-Meier analysis. The added value of family history in prediction of NMIBC prognosis was quantified with Harrell's concordance-index. Hundred (6.8%) NMIBC and 14 (5.6%) MIBC patients reported UBC in first-degree relatives. Positive family history was statistically significantly associated with smaller tumor size and non-significantly with more favorable distribution of other tumor characteristics. In univariable analyses, positive family history correlated with longer RFS (p = 0.11) and PFS (p = 0.04). Hazard ratios for positive vs. negative family history after adjustment for clinicopathological characteristics were 0.75 (95% CI = 0.53-1.07) and 0.45 (95% CI = 0.18-1.12) for RFS and PFS, respectively. Five familial and 48 sporadic MIBC patients (Kaplan-Meier 10-year risk: 41% and 25%) died within 10 years. Family history did not improve the c-index of prediction models. This study shows that a first-degree family history of UBC is not clearly associated with NMIBC prognosis. Family history does not aid in prediction of NMIBC recurrence or progression.
一级亲属中有膀胱癌(UBC)病史会使患UBC的风险增加两倍。阳性家族史对UBC预后的影响尚不清楚。在此,我们研究了一级UBC家族史与UBC患者临床病理特征及预后的相关性。通过查阅病历收集了1995年至2010年诊断的1465例非肌层浸润性膀胱癌(NMIBC)和250例肌层浸润性或转移性膀胱癌(MIBC)患者的详细临床数据。采用竞争风险分析,根据自我报告的UBC家族史比较NMIBC患者的无复发生存期(RFS)和无进展生存期(PFS)。使用Kaplan-Meier分析估计MIBC患者的总生存期。用Harrell一致性指数量化家族史在预测NMIBC预后中的附加值。100例(6.8%)NMIBC患者和14例(5.6%)MIBC患者报告一级亲属中有UBC。阳性家族史与较小的肿瘤大小在统计学上显著相关,与其他肿瘤特征更有利的分布无显著相关性。在单变量分析中,阳性家族史与较长的RFS(p = 0.11)和PFS(p = 0.04)相关。调整临床病理特征后,阳性家族史与阴性家族史的RFS和PFS的风险比分别为0.75(95%CI = 0.53-1.07)和0.45(95%CI = 0.18-1.12)。5例家族性和48例散发性MIBC患者(Kaplan-Meier 10年风险:41%和25%)在10年内死亡。家族史并未改善预测模型的c指数。本研究表明,UBC的一级家族史与NMIBC预后无明显关联。家族史无助于预测NMIBC的复发或进展。